Syndax Pharmaceuticals, Inc. (SNDX) 10-Year Financial Performance & Capital Metrics

SNDX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.Show more

Revenue $24M
EBITDA -$340M -47.7%
Net Income -$319M -52.3%
EPS (Diluted) -3.73 -25.2%
Gross Margin 96.51%
EBITDA Margin -1434.39%
Operating Margin -1434.43%
Net Margin -1346.11%
ROE -75.69% -84.7%
ROIC -68.83% -30.6%
Debt/Equity 1.20 +40576.8%
Interest Coverage -68.91 +93.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)
✓Strong 5Y sales CAGR of 73.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 21.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y73.25%

3Y-44.66%

TTM597.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-4.89%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.28%

ROCE

10Y Avg-50.58%

5Y Avg-34.57%

3Y Avg-45.52%

Latest-57.76%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	627K	1.22M	2.11M	1.52M	1.52M	1.52M	139.71M	0	0	23.68M
Revenue Growth %	-	0.95%	0.73%	-0.28%	0%	0%	91.1%	-1%	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	826K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.03%
Gross Profit+	627K	1.22M	2.11M	1.52M	1.52M	1.52M	139.71M	0	0	22.85M
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	-	-	0.97%
Gross Profit Growth %	-	0.95%	0.73%	-0.28%	0%	0%	91.1%	-1%	-	-
Operating Expenses+	21.14M	44.99M	64.06M	77.39M	59.06M	72.94M	113.49M	151.76M	229.95M	362.53M
OpEx % of Revenue	33.72%	36.87%	30.39%	51.02%	38.93%	48.08%	0.81%	-	-	15.31%
Selling, General & Admin	11.59M	13.32M	15.86M	17.29M	16.06M	22.5M	25.24M	33.26M	66.92M	120.88M
SG&A % of Revenue	18.49%	10.92%	7.52%	11.4%	10.59%	14.84%	0.18%	-	-	5.1%
Research & Development	9.55M	31.66M	48.2M	60.11M	42.99M	50.44M	88.25M	118.5M	163.03M	241.65M
R&D % of Revenue	15.23%	25.95%	22.87%	39.62%	28.34%	33.25%	0.63%	-	-	10.2%
Other Operating Expenses	-37K	0	0	0	0	0	0	0	0	0
Operating Income+	-20.51M	-43.77M	-61.95M	-75.88M	-57.54M	-71.42M	26.22M	-151.76M	-229.95M	-339.67M
Operating Margin %	-32.72%	-35.87%	-29.39%	-50.02%	-37.93%	-47.08%	0.19%	-	-	-14.34%
Operating Income Growth %	0.04%	-1.13%	-0.42%	-0.22%	0.24%	-0.24%	1.37%	-6.79%	-0.52%	-0.48%
EBITDA+	-20.49M	-43.68M	-61.88M	-75.8M	-57.09M	-70.91M	26.26M	-151.72M	-229.94M	-339.66M
EBITDA Margin %	-32.68%	-35.8%	-29.35%	-49.97%	-37.63%	-46.74%	0.19%	-	-	-14.34%
EBITDA Growth %	0.04%	-1.13%	-0.42%	-0.22%	0.25%	-0.24%	1.37%	-6.78%	-0.52%	-0.48%
D&A (Non-Cash Add-back)	21K	89K	76K	78K	451K	515K	43K	33K	12K	8K
EBIT	-20.51M	-43.77M	-61.95M	-73.96M	-56.05M	-70.8M	26.82M	-146.2M	-209.15M	-313.83M
Net Interest Income+	-1.41M	956K	1.42M	1.94M	1.57M	-1.52M	-1.5M	2.73M	20.95M	21.16M
Interest Income	161K	0	0	0	1.57M	841K	403K	5.87M	21.16M	26.09M
Interest Expense	1.57M	956K	1.42M	1.94M	0	2.36M	1.9M	3.14M	208K	4.93M
Other Income/Expense	-3.61M	-706K	1.15M	1.92M	1.49M	-1.74M	-1.29M	2.42M	20.59M	20.91M
Pretax Income+	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Pretax Margin %	-38.47%	-36.45%	-28.84%	-48.75%	-36.95%	-48.23%	0.18%	-	-	-13.46%
Income Tax+	0	-89K	-76K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-24.12M	-44.47M	-60.8M	-73.96M	-55.95M	-73.07M	24.93M	-149.34M	-209.36M	-318.76M
Net Margin %	-38.47%	-36.45%	-28.84%	-48.75%	-36.89%	-48.17%	0.18%	-	-	-13.46%
Net Income Growth %	-0.22%	-0.84%	-0.37%	-0.22%	0.24%	-0.31%	1.34%	-6.99%	-0.4%	-0.52%
Net Income (Continuing)	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.31	-3.04	-2.90	-2.92	-1.84	-1.77	0.48	-2.46	-2.98	-3.73
EPS Growth %	-1.08%	0.29%	0.05%	-0.01%	0.37%	0.04%	1.27%	-6.13%	-0.21%	-0.25%
EPS (Basic)	-4.31	-3.04	-2.90	-2.92	-1.84	-1.77	0.48	-2.46	-2.98	-3.73
Diluted Shares Outstanding	5.59M	14.62M	21M	25.37M	30.49M	41.31M	52.06M	60.76M	70.37M	85.62M
Basic Shares Outstanding	5.59M	14.62M	21M	25.37M	30.49M	41.31M	52.06M	60.76M	70.37M	85.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	88.01M	108.51M	133.44M	83.35M	62.33M	298.86M	448.4M	489.79M	580.88M	603.06M
Cash & Short-Term Investments	87.29M	105.33M	133.22M	80.91M	59.77M	293.06M	446.83M	484.4M	577.58M	582.91M
Cash Only	23.18M	23.84M	35.17M	33.77M	24.61M	115.24M	221.97M	74.36M	295.39M	154.08M
Short-Term Investments	64.11M	81.49M	94.81M	47.14M	35.17M	177.82M	224.87M	410.04M	282.19M	428.83M
Accounts Receivable	258K	306K	377K	253K	116K	175K	429K	4.06M	1.23M	13.87M
Days Sales Outstanding	150.19	91.55	65.28	60.87	27.91	42.11	1.12	-	-	213.81
Inventory	264K	2.41M	-1.44M	1.05M	0	0	0	0	0	366K
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	161.73
Other Current Assets	996K	615K	1.29M	1.79M	2.06M	456K	265K	117K	63K	-2.02M
Total Non-Current Assets+	1.9M	503K	3.74M	592K	1.19M	1.75M	1.26M	7.45M	32M	121.76M
Property, Plant & Equipment	88K	260K	267K	373K	997K	482K	1.26M	1.06M	1.5M	2.02M
Fixed Asset Turnover	7.13x	4.69x	7.90x	4.07x	1.52x	3.15x	110.79x	-	-	11.71x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	3.25M	0	115K	0	0	5.47M	29.83M	119.52M
Other Non-Current Assets	1.81M	243K	231K	219K	82K	1.27M	0	922K	680K	217K
Total Assets+	89.9M	109.01M	137.19M	83.94M	63.52M	300.61M	449.66M	497.24M	612.88M	724.82M
Asset Turnover	0.01x	0.01x	0.02x	0.02x	0.02x	0.01x	0.31x	-	-	0.03x
Asset Growth %	6.01%	0.21%	0.26%	-0.39%	-0.24%	3.73%	0.5%	0.11%	0.23%	0.18%
Total Current Liabilities+	4.85M	10.37M	15.8M	16.11M	18.37M	18.87M	20.68M	29.07M	58.1M	103.55M
Accounts Payable	1.45M	2.38M	2.23M	1.44M	6.18M	3.51M	5.67M	4.35M	9.96M	11.63M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	5.14K
Short-Term Debt	0	0	0	0	0	2.29M	0	0	0	12.12M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	0	0	0	0
Other Current Liabilities	916K	5.13M	9.6M	10.35M	7.39M	3.74M	6.23M	6.55M	35.92M	79.33M
Current Ratio	18.16x	10.47x	8.45x	5.18x	3.39x	15.84x	21.68x	16.85x	10.00x	5.82x
Quick Ratio	18.10x	10.24x	8.54x	5.11x	3.39x	15.84x	21.68x	16.85x	10.00x	5.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-4.76K
Total Non-Current Liabilities+	18.36M	14.51M	17.07M	14.79M	13.56M	29.55M	20.61M	722K	588K	333.14M
Long-Term Debt	0	0	0	0	0	17.83M	19.89M	0	0	331.56M
Capital Lease Obligations	0	0	0	0	419K	101K	711K	722K	588K	1.58M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.92M	288K	310K	136K	5K	1K	0	0	0	0
Total Liabilities	23.2M	24.87M	32.87M	30.89M	31.93M	48.42M	41.29M	29.79M	58.68M	436.69M
Total Debt+	0	0	0	0	897K	20.54M	20.97M	1.16M	1.64M	345.74M
Net Debt	-23.18M	-23.84M	-35.17M	-33.77M	-23.71M	-94.71M	-201M	-73.19M	-293.76M	191.66M
Debt / Equity	-	-	-	-	0.03x	0.08x	0.05x	0.00x	0.00x	1.20x
Debt / EBITDA	-	-	-	-	-	-	0.80x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-7.65x	-	-	-
Interest Coverage	-13.02x	-45.78x	-43.60x	-39.07x	-	-30.30x	13.81x	-48.38x	-1105.55x	-68.91x
Total Equity+	66.7M	84.14M	104.32M	53.05M	31.6M	252.19M	408.37M	467.45M	554.2M	288.12M
Equity Growth %	12.67%	0.26%	0.24%	-0.49%	-0.4%	6.98%	0.62%	0.14%	0.19%	-0.48%
Book Value per Share	11.93	5.76	4.97	2.09	1.04	6.11	7.84	7.69	7.88	3.37
Total Shareholders' Equity	66.7M	84.14M	104.32M	53.05M	31.6M	252.19M	408.37M	467.45M	554.2M	288.12M
Common Stock	1K	2K	2K	2K	3K	5K	6K	7K	8K	9K
Retained Earnings	-259.68M	-305.29M	-366.11M	-439.42M	-495.47M	-568.63M	-543.7M	-693.04M	-902.4M	-1.22B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	28K	56K	-143K	-25K	0	-4K	45K	-806K	218K	163K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.43M	-35.16M	-47.37M	-68.53M	-50.61M	-71.26M	29.13M	-133.68M	-160.6M	-274.9M
Operating CF Margin %	-3.87%	-28.82%	-22.47%	-45.18%	-33.36%	-46.97%	0.21%	-	-	-11.61%
Operating CF Growth %	0.83%	-13.48%	-0.35%	-0.45%	0.26%	-0.41%	1.41%	-5.59%	-0.2%	-0.71%
Net Income	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Depreciation & Amortization	21K	89K	76K	78K	92K	89K	43K	33K	12K	8K
Stock-Based Compensation	3.88M	4.71M	5.45M	6.2M	6M	9.06M	13.32M	16.02M	30.95M	43.03M
Deferred Taxes	2.47M	1.58M	223K	-558K	-780K	0	255K	0	0	0
Other Non-Cash Items	762K	25K	8K	11K	359K	686K	187K	-2.04M	-14.06M	-12.45M
Working Capital Changes	14.56M	2.92M	7.67M	-302K	-241K	-7.93M	-9.6M	1.66M	31.86M	13.27M
Change in Receivables	0	0	0	0	0	0	0	-3.47M	0	-11.24M
Change in Inventory	0	0	0	0	0	0	0	3.47M	0	-366K
Change in Payables	1.04M	923K	-194K	-792K	4.74M	-2.67M	2.16M	-1.32M	5.61M	1.67M
Cash from Investing+	-61.67M	-18.38M	-17.03M	51.4M	12.78M	-142.53M	-40.87M	-186.19M	117.61M	-219.78M
Capital Expenditures	-49K	-261K	-84K	-187K	0	0	-129K	-225K	0	0
CapEx % of Revenue	0.08%	0.21%	0.04%	0.12%	-	-	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-118K	-97K	45K	51.59K	12.78K	0	-40.74K	225K	0	0
Cash from Financing+	77.27M	54.2M	75.72M	15.73M	28.57M	304.42M	118.46M	172.25M	264.13M	353.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-2.6M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.06M	4.65M	374K	232K	360K	6.63M	32.13M	11.86M	6.04M	343.65M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.48M	-35.42M	-47.45M	-68.72M	-50.61M	-71.26M	29M	-133.9M	-160.6M	-274.9M
FCF Margin %	-3.95%	-29.03%	-22.51%	-45.3%	-33.36%	-46.97%	0.21%	-	-	-11.61%
FCF Growth %	0.83%	-13.3%	-0.34%	-0.45%	0.26%	-0.41%	1.41%	-5.62%	-0.2%	-0.71%
FCF per Share	-0.44	-2.42	-2.26	-2.71	-1.66	-1.73	0.56	-2.20	-2.28	-3.21
FCF Conversion (FCF/Net Income)	0.10x	0.79x	0.78x	0.93x	0.90x	0.98x	1.17x	0.90x	0.77x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-79.1%	-58.97%	-64.53%	-94%	-132.21%	-51.5%	7.55%	-34.1%	-40.98%	-75.69%
Return on Invested Capital (ROIC)	-73.83%	-63.24%	-71.79%	-128.71%	-317.71%	-64.79%	10.78%	-37.84%	-52.69%	-68.83%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	-	-	96.51%
Net Margin	-3846.73%	-3645.25%	-2884.35%	-4875.48%	-3688.53%	-4816.68%	17.84%	-	-	-1346.11%
Debt / Equity	-	-	-	-	0.03x	0.08x	0.05x	0.00x	0.00x	1.20x
Interest Coverage	-13.02x	-45.78x	-43.60x	-39.07x	-	-30.30x	13.81x	-48.38x	-1105.55x	-68.91x
FCF Conversion	0.10x	0.79x	0.78x	0.93x	0.90x	0.98x	1.17x	0.90x	0.77x	0.86x
Revenue Growth	-	94.58%	72.79%	-28.04%	0%	0%	9109.56%	-100%	-	-

Revenue by Segment

	2024
Milestone Revenue	16M
Milestone Revenue Growth	-
Net Product Revenues	7.68M
Net Product Revenues Growth	-

Frequently Asked Questions

Growth & Financials

Syndax Pharmaceuticals, Inc. (SNDX) reported $111.6M in revenue for fiscal year 2024.

Syndax Pharmaceuticals, Inc. (SNDX) grew revenue by 0.0% over the past year. Growth has been modest.

Syndax Pharmaceuticals, Inc. (SNDX) reported a net loss of $311.6M for fiscal year 2024.

Dividend & Returns

Syndax Pharmaceuticals, Inc. (SNDX) has a return on equity (ROE) of -75.7%. Negative ROE indicates the company is unprofitable.

Syndax Pharmaceuticals, Inc. (SNDX) had negative free cash flow of $311.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Syndax Pharmaceuticals, Inc. (SNDX) 10-Year Financial Performance & Capital Metrics

SNDX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $24M
EBITDA -$340M -47.7%
Net Income -$319M -52.3%
EPS (Diluted) -3.73 -25.2%
Gross Margin 96.51%
EBITDA Margin -1434.39%
Operating Margin -1434.43%
Net Margin -1346.11%
ROE -75.69% -84.7%
ROIC -68.83% -30.6%
Debt/Equity 1.20 +40576.8%
Interest Coverage -68.91 +93.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)
✓Strong 5Y sales CAGR of 73.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 21.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y73.25%

3Y-44.66%

TTM597.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-4.89%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.28%

ROCE

10Y Avg-50.58%

5Y Avg-34.57%

3Y Avg-45.52%

Latest-57.76%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	627K	1.22M	2.11M	1.52M	1.52M	1.52M	139.71M	0	0	23.68M
Revenue Growth %	-	0.95%	0.73%	-0.28%	0%	0%	91.1%	-1%	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	826K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.03%
Gross Profit+	627K	1.22M	2.11M	1.52M	1.52M	1.52M	139.71M	0	0	22.85M
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	-	-	0.97%
Gross Profit Growth %	-	0.95%	0.73%	-0.28%	0%	0%	91.1%	-1%	-	-
Operating Expenses+	21.14M	44.99M	64.06M	77.39M	59.06M	72.94M	113.49M	151.76M	229.95M	362.53M
OpEx % of Revenue	33.72%	36.87%	30.39%	51.02%	38.93%	48.08%	0.81%	-	-	15.31%
Selling, General & Admin	11.59M	13.32M	15.86M	17.29M	16.06M	22.5M	25.24M	33.26M	66.92M	120.88M
SG&A % of Revenue	18.49%	10.92%	7.52%	11.4%	10.59%	14.84%	0.18%	-	-	5.1%
Research & Development	9.55M	31.66M	48.2M	60.11M	42.99M	50.44M	88.25M	118.5M	163.03M	241.65M
R&D % of Revenue	15.23%	25.95%	22.87%	39.62%	28.34%	33.25%	0.63%	-	-	10.2%
Other Operating Expenses	-37K	0	0	0	0	0	0	0	0	0
Operating Income+	-20.51M	-43.77M	-61.95M	-75.88M	-57.54M	-71.42M	26.22M	-151.76M	-229.95M	-339.67M
Operating Margin %	-32.72%	-35.87%	-29.39%	-50.02%	-37.93%	-47.08%	0.19%	-	-	-14.34%
Operating Income Growth %	0.04%	-1.13%	-0.42%	-0.22%	0.24%	-0.24%	1.37%	-6.79%	-0.52%	-0.48%
EBITDA+	-20.49M	-43.68M	-61.88M	-75.8M	-57.09M	-70.91M	26.26M	-151.72M	-229.94M	-339.66M
EBITDA Margin %	-32.68%	-35.8%	-29.35%	-49.97%	-37.63%	-46.74%	0.19%	-	-	-14.34%
EBITDA Growth %	0.04%	-1.13%	-0.42%	-0.22%	0.25%	-0.24%	1.37%	-6.78%	-0.52%	-0.48%
D&A (Non-Cash Add-back)	21K	89K	76K	78K	451K	515K	43K	33K	12K	8K
EBIT	-20.51M	-43.77M	-61.95M	-73.96M	-56.05M	-70.8M	26.82M	-146.2M	-209.15M	-313.83M
Net Interest Income+	-1.41M	956K	1.42M	1.94M	1.57M	-1.52M	-1.5M	2.73M	20.95M	21.16M
Interest Income	161K	0	0	0	1.57M	841K	403K	5.87M	21.16M	26.09M
Interest Expense	1.57M	956K	1.42M	1.94M	0	2.36M	1.9M	3.14M	208K	4.93M
Other Income/Expense	-3.61M	-706K	1.15M	1.92M	1.49M	-1.74M	-1.29M	2.42M	20.59M	20.91M
Pretax Income+	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Pretax Margin %	-38.47%	-36.45%	-28.84%	-48.75%	-36.95%	-48.23%	0.18%	-	-	-13.46%
Income Tax+	0	-89K	-76K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-24.12M	-44.47M	-60.8M	-73.96M	-55.95M	-73.07M	24.93M	-149.34M	-209.36M	-318.76M
Net Margin %	-38.47%	-36.45%	-28.84%	-48.75%	-36.89%	-48.17%	0.18%	-	-	-13.46%
Net Income Growth %	-0.22%	-0.84%	-0.37%	-0.22%	0.24%	-0.31%	1.34%	-6.99%	-0.4%	-0.52%
Net Income (Continuing)	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.31	-3.04	-2.90	-2.92	-1.84	-1.77	0.48	-2.46	-2.98	-3.73
EPS Growth %	-1.08%	0.29%	0.05%	-0.01%	0.37%	0.04%	1.27%	-6.13%	-0.21%	-0.25%
EPS (Basic)	-4.31	-3.04	-2.90	-2.92	-1.84	-1.77	0.48	-2.46	-2.98	-3.73
Diluted Shares Outstanding	5.59M	14.62M	21M	25.37M	30.49M	41.31M	52.06M	60.76M	70.37M	85.62M
Basic Shares Outstanding	5.59M	14.62M	21M	25.37M	30.49M	41.31M	52.06M	60.76M	70.37M	85.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	88.01M	108.51M	133.44M	83.35M	62.33M	298.86M	448.4M	489.79M	580.88M	603.06M
Cash & Short-Term Investments	87.29M	105.33M	133.22M	80.91M	59.77M	293.06M	446.83M	484.4M	577.58M	582.91M
Cash Only	23.18M	23.84M	35.17M	33.77M	24.61M	115.24M	221.97M	74.36M	295.39M	154.08M
Short-Term Investments	64.11M	81.49M	94.81M	47.14M	35.17M	177.82M	224.87M	410.04M	282.19M	428.83M
Accounts Receivable	258K	306K	377K	253K	116K	175K	429K	4.06M	1.23M	13.87M
Days Sales Outstanding	150.19	91.55	65.28	60.87	27.91	42.11	1.12	-	-	213.81
Inventory	264K	2.41M	-1.44M	1.05M	0	0	0	0	0	366K
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	161.73
Other Current Assets	996K	615K	1.29M	1.79M	2.06M	456K	265K	117K	63K	-2.02M
Total Non-Current Assets+	1.9M	503K	3.74M	592K	1.19M	1.75M	1.26M	7.45M	32M	121.76M
Property, Plant & Equipment	88K	260K	267K	373K	997K	482K	1.26M	1.06M	1.5M	2.02M
Fixed Asset Turnover	7.13x	4.69x	7.90x	4.07x	1.52x	3.15x	110.79x	-	-	11.71x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	3.25M	0	115K	0	0	5.47M	29.83M	119.52M
Other Non-Current Assets	1.81M	243K	231K	219K	82K	1.27M	0	922K	680K	217K
Total Assets+	89.9M	109.01M	137.19M	83.94M	63.52M	300.61M	449.66M	497.24M	612.88M	724.82M
Asset Turnover	0.01x	0.01x	0.02x	0.02x	0.02x	0.01x	0.31x	-	-	0.03x
Asset Growth %	6.01%	0.21%	0.26%	-0.39%	-0.24%	3.73%	0.5%	0.11%	0.23%	0.18%
Total Current Liabilities+	4.85M	10.37M	15.8M	16.11M	18.37M	18.87M	20.68M	29.07M	58.1M	103.55M
Accounts Payable	1.45M	2.38M	2.23M	1.44M	6.18M	3.51M	5.67M	4.35M	9.96M	11.63M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	5.14K
Short-Term Debt	0	0	0	0	0	2.29M	0	0	0	12.12M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	0	0	0	0
Other Current Liabilities	916K	5.13M	9.6M	10.35M	7.39M	3.74M	6.23M	6.55M	35.92M	79.33M
Current Ratio	18.16x	10.47x	8.45x	5.18x	3.39x	15.84x	21.68x	16.85x	10.00x	5.82x
Quick Ratio	18.10x	10.24x	8.54x	5.11x	3.39x	15.84x	21.68x	16.85x	10.00x	5.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-4.76K
Total Non-Current Liabilities+	18.36M	14.51M	17.07M	14.79M	13.56M	29.55M	20.61M	722K	588K	333.14M
Long-Term Debt	0	0	0	0	0	17.83M	19.89M	0	0	331.56M
Capital Lease Obligations	0	0	0	0	419K	101K	711K	722K	588K	1.58M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.92M	288K	310K	136K	5K	1K	0	0	0	0
Total Liabilities	23.2M	24.87M	32.87M	30.89M	31.93M	48.42M	41.29M	29.79M	58.68M	436.69M
Total Debt+	0	0	0	0	897K	20.54M	20.97M	1.16M	1.64M	345.74M
Net Debt	-23.18M	-23.84M	-35.17M	-33.77M	-23.71M	-94.71M	-201M	-73.19M	-293.76M	191.66M
Debt / Equity	-	-	-	-	0.03x	0.08x	0.05x	0.00x	0.00x	1.20x
Debt / EBITDA	-	-	-	-	-	-	0.80x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-7.65x	-	-	-
Interest Coverage	-13.02x	-45.78x	-43.60x	-39.07x	-	-30.30x	13.81x	-48.38x	-1105.55x	-68.91x
Total Equity+	66.7M	84.14M	104.32M	53.05M	31.6M	252.19M	408.37M	467.45M	554.2M	288.12M
Equity Growth %	12.67%	0.26%	0.24%	-0.49%	-0.4%	6.98%	0.62%	0.14%	0.19%	-0.48%
Book Value per Share	11.93	5.76	4.97	2.09	1.04	6.11	7.84	7.69	7.88	3.37
Total Shareholders' Equity	66.7M	84.14M	104.32M	53.05M	31.6M	252.19M	408.37M	467.45M	554.2M	288.12M
Common Stock	1K	2K	2K	2K	3K	5K	6K	7K	8K	9K
Retained Earnings	-259.68M	-305.29M	-366.11M	-439.42M	-495.47M	-568.63M	-543.7M	-693.04M	-902.4M	-1.22B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	28K	56K	-143K	-25K	0	-4K	45K	-806K	218K	163K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.43M	-35.16M	-47.37M	-68.53M	-50.61M	-71.26M	29.13M	-133.68M	-160.6M	-274.9M
Operating CF Margin %	-3.87%	-28.82%	-22.47%	-45.18%	-33.36%	-46.97%	0.21%	-	-	-11.61%
Operating CF Growth %	0.83%	-13.48%	-0.35%	-0.45%	0.26%	-0.41%	1.41%	-5.59%	-0.2%	-0.71%
Net Income	-24.12M	-44.47M	-60.8M	-73.96M	-56.05M	-73.16M	24.93M	-149.34M	-209.36M	-318.76M
Depreciation & Amortization	21K	89K	76K	78K	92K	89K	43K	33K	12K	8K
Stock-Based Compensation	3.88M	4.71M	5.45M	6.2M	6M	9.06M	13.32M	16.02M	30.95M	43.03M
Deferred Taxes	2.47M	1.58M	223K	-558K	-780K	0	255K	0	0	0
Other Non-Cash Items	762K	25K	8K	11K	359K	686K	187K	-2.04M	-14.06M	-12.45M
Working Capital Changes	14.56M	2.92M	7.67M	-302K	-241K	-7.93M	-9.6M	1.66M	31.86M	13.27M
Change in Receivables	0	0	0	0	0	0	0	-3.47M	0	-11.24M
Change in Inventory	0	0	0	0	0	0	0	3.47M	0	-366K
Change in Payables	1.04M	923K	-194K	-792K	4.74M	-2.67M	2.16M	-1.32M	5.61M	1.67M
Cash from Investing+	-61.67M	-18.38M	-17.03M	51.4M	12.78M	-142.53M	-40.87M	-186.19M	117.61M	-219.78M
Capital Expenditures	-49K	-261K	-84K	-187K	0	0	-129K	-225K	0	0
CapEx % of Revenue	0.08%	0.21%	0.04%	0.12%	-	-	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-118K	-97K	45K	51.59K	12.78K	0	-40.74K	225K	0	0
Cash from Financing+	77.27M	54.2M	75.72M	15.73M	28.57M	304.42M	118.46M	172.25M	264.13M	353.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-2.6M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.06M	4.65M	374K	232K	360K	6.63M	32.13M	11.86M	6.04M	343.65M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-2.48M	-35.42M	-47.45M	-68.72M	-50.61M	-71.26M	29M	-133.9M	-160.6M	-274.9M
FCF Margin %	-3.95%	-29.03%	-22.51%	-45.3%	-33.36%	-46.97%	0.21%	-	-	-11.61%
FCF Growth %	0.83%	-13.3%	-0.34%	-0.45%	0.26%	-0.41%	1.41%	-5.62%	-0.2%	-0.71%
FCF per Share	-0.44	-2.42	-2.26	-2.71	-1.66	-1.73	0.56	-2.20	-2.28	-3.21
FCF Conversion (FCF/Net Income)	0.10x	0.79x	0.78x	0.93x	0.90x	0.98x	1.17x	0.90x	0.77x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-79.1%	-58.97%	-64.53%	-94%	-132.21%	-51.5%	7.55%	-34.1%	-40.98%	-75.69%
Return on Invested Capital (ROIC)	-73.83%	-63.24%	-71.79%	-128.71%	-317.71%	-64.79%	10.78%	-37.84%	-52.69%	-68.83%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	-	-	96.51%
Net Margin	-3846.73%	-3645.25%	-2884.35%	-4875.48%	-3688.53%	-4816.68%	17.84%	-	-	-1346.11%
Debt / Equity	-	-	-	-	0.03x	0.08x	0.05x	0.00x	0.00x	1.20x
Interest Coverage	-13.02x	-45.78x	-43.60x	-39.07x	-	-30.30x	13.81x	-48.38x	-1105.55x	-68.91x
FCF Conversion	0.10x	0.79x	0.78x	0.93x	0.90x	0.98x	1.17x	0.90x	0.77x	0.86x
Revenue Growth	-	94.58%	72.79%	-28.04%	0%	0%	9109.56%	-100%	-	-

Revenue by Segment

	2024
Milestone Revenue	16M
Milestone Revenue Growth	-
Net Product Revenues	7.68M
Net Product Revenues Growth	-

Frequently Asked Questions

Growth & Financials

Syndax Pharmaceuticals, Inc. (SNDX) reported $111.6M in revenue for fiscal year 2024.

Syndax Pharmaceuticals, Inc. (SNDX) grew revenue by 0.0% over the past year. Growth has been modest.

Syndax Pharmaceuticals, Inc. (SNDX) reported a net loss of $311.6M for fiscal year 2024.

Dividend & Returns

Syndax Pharmaceuticals, Inc. (SNDX) has a return on equity (ROE) of -75.7%. Negative ROE indicates the company is unprofitable.

Syndax Pharmaceuticals, Inc. (SNDX) had negative free cash flow of $311.0M in fiscal year 2024, likely due to heavy capital investments.